<p>Sanara MedTech（纳斯达克代码：SMTI - 获取免费报告）于周三发布了季度财报。该公司报告季度每股收益为 0.09 美元，超出市场共识预期的（0.24 美元）0.33 美元，Zacks 报道。Sanara MedTech 的股本回报率为负 26.43%，净利润率为负 10.22%。</p>
<p>获取 <strong>Sanara MedTech</strong> 的提醒：</p>
<h2>Sanara MedTech 价格表现</h2>
<p>周三中午交易时，Sanara MedTech 股票下跌 6.66 美元，达到 21.38 美元。该公司交易了 225,405 股，较其平均交易量 32,604 股有所增加。该公司的市值为 1.9032 亿美元，市盈率为-18.48，贝塔值为 1.21。该公司的 50 日简单移动平均为 31.28 美元，200 日简单移动平均为 30.10 美元。Sanara MedTech 的 12 个月低点为 20.79 美元，12 个月高点为 39.08 美元。该公司的债务与股本比率为 1.25，流动比率为 2.26，速动比率为 2.03。</p>
<h2>对 Sanara MedTech 的对冲基金看法</h2>
<p>机构投资者最近调整了对该公司的持股。Lazard Asset Management LLC 在第二季度将其在 Sanara MedTech 的持股增加了 63,100.0%。Lazard Asset Management LLC 目前拥有 3,160 股该公司的股票，价值 89,000 美元，此前在上个季度增持了 3,155 股。Rhumbline Advisers 在第一季度将其在 Sanara MedTech 的持股增加了 14.9%。Rhumbline Advisers 目前拥有 3,714 股该公司的股票，价值 115,000 美元，此前在上个季度增持了 483 股。摩根大通在第三季度将其在 Sanara MedTech 的持股增加了 26.5%。摩根大通目前拥有 11,057 股该公司的股票，价值 351,000 美元，此前在此期间增持了 2,315 股。汇丰控股在第二季度收购了 Sanara MedTech 的新股份，价值约 382,000 美元。最后，Marshall Wace LLP 在第二季度将其在 Sanara MedTech 的持股增加了 144.3%。Marshall Wace LLP 目前拥有 71,511 股该公司的股票，价值 2,030,000 美元，此前在上个季度增持了 42,237 股。机构投资者和对冲基金持有该公司 8.10% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>一些研究分析师最近对该股票发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Sanara MedTech 的 “卖出（e+）” 评级。HC Wainwright 将 Sanara MedTech 的目标价从 53.00 美元上调至 54.00 美元，并在 8 月 18 日的报告中给予该股票 “买入” 评级。最后，华尔街 Zen 在 11 月 1 日的研究报告中将 Sanara MedTech 的评级从 “买入” 下调至 “持有”。两位研究分析师对该股票给予了 “买入” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，Sanara MedTech 目前的共识评级为 “持有”，平均目标价为 50.00 美元。</p>
<p><strong>查看我们最新的 SMTI 股票报告</strong></p>
<h2>关于 Sanara MedTech</h2>
<p>（获取免费报告）</p>
<p>Sanara MedTech Inc 是一家医疗技术公司，开发、营销和分销外科、伤口和皮肤护理产品及服务，面向美国的医生、医院、诊所和后期护理机构。该公司提供 CellerateRX Surgical，这是一种 I 型牛胶原蛋白的医疗水解物，适用于外科、创伤以及部分和全层伤口的管理，以及一度和二度烧伤；以及 HYCOL，这是一种 I 型牛胶原蛋白的医疗水解物，旨在管理全层和部分层伤口，包括压疮、静脉和动脉腿部溃疡以及糖尿病足溃疡。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Sanara MedTech</li>
<li>成长股：它们是什么，它们不是</li>
<li>Papa John's 27 亿美元收购提议：未开发价值的价格</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>高通是上涨 40% 还是下跌 20%？两种对立观点</li>
<li>FAANG 股票是什么，它们是好投资吗？</li>
<li>Guardian Pharmacy 股票因第三季度强劲表现和乐观预测而上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01USQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01USQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Sanara MedTech 吗？</h2>
<p>在你考虑 Sanara MedTech 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，以便在更广泛的市场注意到之前购买……而 Sanara MedTech 并不在名单上。</p>
<p>虽然 Sanara MedTech 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SMTI

<p>Sanara MedTech 宣布季度每股收益为 0.09 美元，超过分析师预期的 -0.24 美元。尽管净利润率为 -10.22% 和股本回报率为 26.43%，但股价仍下跌 6.66 美元，至 21.38 美元。机构投资者调整了持股，Lazard Asset Management 显著增加了股份。分析师的评级各不相同，普遍维持 “持有” 评级，平均目标价为 50.00 美元。Sanara MedTech 在美国开发外科和伤口护理产品</p>

<p>Sanara MedTech (NASDAQ:SMTI - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.33, Zacks reports. Sanara MedTech had a negative return on equity of 26.43% and a negative net margin of 10.22%.</p>
<div class="lb-trans"><p>Sanara MedTech（纳斯达克代码：SMTI - 获取免费报告）于周三发布了季度财报。该公司报告季度每股收益为 0.09 美元，超出市场共识预期的（0.24 美元）0.33 美元，Zacks 报道。Sanara MedTech 的股本回报率为负 26.43%，净利润率为负 10.22%。</p>
</div><p>Get <strong>Sanara MedTech</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sanara MedTech</strong> 的提醒：</p>
</div><h2>Sanara MedTech Price Performance</h2>
<div class="lb-trans"><h2>Sanara MedTech 价格表现</h2>
</div><p>Sanara MedTech stock traded down $6.66 during mid-day trading on Wednesday, reaching $21.38. 225,405 shares of the company were exchanged, compared to its average volume of 32,604. The firm has a market cap of $190.32 million, a PE ratio of -18.48 and a beta of 1.21. The company has a fifty day simple moving average of $31.28 and a 200-day simple moving average of $30.10. Sanara MedTech has a 12 month low of $20.79 and a 12 month high of $39.08. The company has a debt-to-equity ratio of 1.25, a current ratio of 2.26 and a quick ratio of 2.03.</p>
<div class="lb-trans"><p>周三中午交易时，Sanara MedTech 股票下跌 6.66 美元，达到 21.38 美元。该公司交易了 225,405 股，较其平均交易量 32,604 股有所增加。该公司的市值为 1.9032 亿美元，市盈率为-18.48，贝塔值为 1.21。该公司的 50 日简单移动平均为 31.28 美元，200 日简单移动平均为 30.10 美元。Sanara MedTech 的 12 个月低点为 20.79 美元，12 个月高点为 39.08 美元。该公司的债务与股本比率为 1.25，流动比率为 2.26，速动比率为 2.03。</p>
</div><h2>Hedge Funds Weigh In On Sanara MedTech</h2>
<div class="lb-trans"><h2>对 Sanara MedTech 的对冲基金看法</h2>
</div><p>Institutional investors have recently modified their holdings of the business. Lazard Asset Management LLC lifted its holdings in shares of Sanara MedTech by 63,100.0% in the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company's stock worth $89,000 after acquiring an additional 3,155 shares during the last quarter. Rhumbline Advisers raised its position in shares of Sanara MedTech by 14.9% during the first quarter. Rhumbline Advisers now owns 3,714 shares of the company's stock worth $115,000 after acquiring an additional 483 shares during the last quarter. JPMorgan Chase &amp; Co. lifted its position in shares of Sanara MedTech by 26.5% in the 3rd quarter. JPMorgan Chase &amp; Co. now owns 11,057 shares of the company's stock worth $351,000 after purchasing an additional 2,315 shares during the period. Hsbc Holdings PLC acquired a new stake in Sanara MedTech during the 2nd quarter worth about $382,000. Finally, Marshall Wace LLP increased its holdings in Sanara MedTech by 144.3% in the second quarter. Marshall Wace LLP now owns 71,511 shares of the company's stock worth $2,030,000 after purchasing an additional 42,237 shares in the last quarter. Institutional investors and hedge funds own 8.10% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该公司的持股。Lazard Asset Management LLC 在第二季度将其在 Sanara MedTech 的持股增加了 63,100.0%。Lazard Asset Management LLC 目前拥有 3,160 股该公司的股票，价值 89,000 美元，此前在上个季度增持了 3,155 股。Rhumbline Advisers 在第一季度将其在 Sanara MedTech 的持股增加了 14.9%。Rhumbline Advisers 目前拥有 3,714 股该公司的股票，价值 115,000 美元，此前在上个季度增持了 483 股。摩根大通在第三季度将其在 Sanara MedTech 的持股增加了 26.5%。摩根大通目前拥有 11,057 股该公司的股票，价值 351,000 美元，此前在此期间增持了 2,315 股。汇丰控股在第二季度收购了 Sanara MedTech 的新股份，价值约 382,000 美元。最后，Marshall Wace LLP 在第二季度将其在 Sanara MedTech 的持股增加了 144.3%。Marshall Wace LLP 目前拥有 71,511 股该公司的股票，价值 2,030,000 美元，此前在上个季度增持了 42,237 股。机构投资者和对冲基金持有该公司 8.10% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research analysts have recently issued reports on the stock. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Sanara MedTech in a research note on Wednesday, October 8th. HC Wainwright increased their price objective on Sanara MedTech from $53.00 to $54.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, August 18th. Finally, Wall Street Zen downgraded Sanara MedTech from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 1st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Sanara MedTech presently has a consensus rating of &#34;Hold&#34; and an average price target of $50.00.</p>
<div class="lb-trans"><p>一些研究分析师最近对该股票发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Sanara MedTech 的 “卖出（e+）” 评级。HC Wainwright 将 Sanara MedTech 的目标价从 53.00 美元上调至 54.00 美元，并在 8 月 18 日的报告中给予该股票 “买入” 评级。最后，华尔街 Zen 在 11 月 1 日的研究报告中将 Sanara MedTech 的评级从 “买入” 下调至 “持有”。两位研究分析师对该股票给予了 “买入” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，Sanara MedTech 目前的共识评级为 “持有”，平均目标价为 50.00 美元。</p>
</div><p><strong>View Our Latest Stock Report on SMTI</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 SMTI 股票报告</strong></p>
</div><h2>About Sanara MedTech</h2>
<div class="lb-trans"><h2>关于 Sanara MedTech</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.</p>
<div class="lb-trans"><p>Sanara MedTech Inc 是一家医疗技术公司，开发、营销和分销外科、伤口和皮肤护理产品及服务，面向美国的医生、医院、诊所和后期护理机构。该公司提供 CellerateRX Surgical，这是一种 I 型牛胶原蛋白的医疗水解物，适用于外科、创伤以及部分和全层伤口的管理，以及一度和二度烧伤；以及 HYCOL，这是一种 I 型牛胶原蛋白的医疗水解物，旨在管理全层和部分层伤口，包括压疮、静脉和动脉腿部溃疡以及糖尿病足溃疡。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Sanara MedTech</li>
<li>Growth Stocks: What They Are, What They Are Not</li>
<li>Papa John's $2.7 Billion Takeover Bid: A Price on Untapped Value</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Is Qualcomm Up 40% or Down 20%? 2 Contrarian Takes</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Guardian Pharmacy Stock Pops on Q3 Strength and Upbeat Forecast</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Sanara MedTech</li>
<li>成长股：它们是什么，它们不是</li>
<li>Papa John's 27 亿美元收购提议：未开发价值的价格</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>高通是上涨 40% 还是下跌 20%？两种对立观点</li>
<li>FAANG 股票是什么，它们是好投资吗？</li>
<li>Guardian Pharmacy 股票因第三季度强劲表现和乐观预测而上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01USQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SMTI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sanara MedTech Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sanara MedTech 吗？</h2>
</div><p>Before you consider Sanara MedTech, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Sanara MedTech 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanara MedTech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，以便在更广泛的市场注意到之前购买……而 Sanara MedTech 并不在名单上。</p>
</div><p>While Sanara MedTech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sanara MedTech 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sanara MedTech（NASDAQ 代码：SMTI）公布财报结果